Harvard Bioscience Announces Allocation of Tax Basis for Spin-Off of Harvard Apparatus Regenerative Technology

Harvard Bioscience Announces Allocation of Tax Basis for Spin-Off of Harvard
Apparatus Regenerative Technology

HOLLISTON, Mass., Nov. 13, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.
(Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range
of tools to advance life science research, announced the allocation of tax
basis resulting from the tax-free spin-off of Harvard Apparatus Regenerative
Technology, Inc. Based on the relative fair market values of the respective
companies on November 1, 2013, the first day of trading after distribution,
23.63 percent of a stockholder`s pre-distribution tax basis in Harvard
Bioscience common stock should be allocated to the shares of common stock in
Harvard Apparatus Regenerative Technology received pursuant to the
distribution described in the Information Statement of Harvard Apparatus
Regenerative Technology dated October 17, 2013.

A copy of the Form 8937, Report of Organizational Actions Affecting Basis of
Securities, is available in the Investor Relations section of Harvard
Bioscience's website at www.harvardbioscience.com.

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer
of a broad range of specialized products, primarily apparatus and scientific
instruments, used to advance life science research. Our products are sold to
thousands of researchers in over 100 countries primarily through our 850 page
catalog (and various other specialty catalogs), our website, through
distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and
via our field sales organization. HBIO has sales and manufacturing operations
in the United States, the United Kingdom, Germany, Sweden and Spain with
additional facilities in France and Canada. For more information, please visit
our website at www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6426

For investor inquiries, please call (508) 893-8066. Press releases may be
found on our web site.

CONTACT: Jeffrey A. Duchemin
         President and Chief Executive Officer
         (508) 893-8999
        
         Investor Relations:
         Dian Griesel Inc.
         Cheryl Schneider
         (212) 825-3210
        
         Public Relations:
         Dian Griesel Inc.
         Susan Forman or Laura Radocaj
         (212) 825-3210

Harvard Bioscience, Inc. Logo